Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07093346 Sponsor: University of Nottingham Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT07093346
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Main study participants:

  • You have been diagnosed with a liver condition called MASLD (also known as fatty liver disease), with test results showing more than 5% fat in your liver from a scan or biopsy done recently.
  • You are willing and able to sign a consent form agreeing to take part in the study.
  • You are 18 years old or older, have a body mass index (BMI) between 18.5 and 39.9, and your weight has stayed roughly the same (within 3 kg) over the past 3 months.
  • If you have diabetes, your blood sugar levels must be well controlled, with an HbA1c (a measure of average blood sugar) below 7.0%.
  • You are able to have a FibroScan™, which is a painless liver scan used to measure liver stiffness and fat.

Healthy volunteers joining for MRI scans only:

  • You are willing and able to sign a consent form agreeing to take part.
  • You are 18 years old or older.
  • A recent FibroScan™ (within the past 6 months) shows that your liver fat and stiffness levels are within a healthy range (confirm with trial site).

Who may not be able to join:

Main study:

  • You are allergic to soya, milk, or chocolate.
  • You are allergic to pectin (a substance found naturally in fruit).
  • You follow a vegan diet.
  • You have an eating disorder, difficulty eating, or a gut/digestive condition such as coeliac disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or a condition where your stomach empties too slowly (gastroparesis).
  • You have a long-term condition that causes malnutrition (not getting enough nutrients).
  • You have had major surgery in the past that might make it hard for you to fully take part in or complete the study.
  • You have had surgery on your intestines or gut that affects how you eat or digest food, including weight-loss (bariatric) surgery.
  • You have taken antibiotics, antifungal medicines, probiotics, or prebiotics in the 90 days before the study starts.
  • You are currently taking certain medications, specifically immunosuppressants (medicines that reduce your immune system), amiodarone, or perhexiline (certain heart medicines).
  • You are currently following, or planning to start, a commercial weight-loss diet or programme, or are taking any weight-loss medication or herbal weight-loss products.
  • You have previously had side effects from taking probiotics or prebiotics.
  • You have a current or past history of a psychiatric (mental health) illness.
  • You have a current or past history of a neurological condition (a condition affecting the brain or nerves), such as epilepsy.
  • You have other liver problems beyond fatty liver disease.
  • You have a rare inherited metabolic condition affecting how your body processes fats or other substances (confirm with trial site for specific conditions).
  • Your weight has changed by more than 3 kg in the past 3 months.
  • You have uncontrolled diabetes, an active cancer, or a long-term infection.
  • You currently have symptoms of an active infection (such as a fever or illness).
  • You drink more than 21 units of alcohol per week (if male) or more than 14 units per week (if female).
  • You are pregnant, breastfeeding, or currently trying to become pregnant.
  • You have taken part in another clinical trial within the last 3 months.

For the optional MRI scan part of the study (applies to both patients and healthy volunteers):

  • You have a pacemaker, defibrillator, neurostimulator, certain medical implants, or metal objects in your body (such as bullets, shrapnel, or metal fragments), as these can be dangerous inside an MRI scanner.
  • You have a history of a metal fragment in your eye or a penetrating eye injury.
  • You have difficulty breathing, cannot lie flat, or have a condition that could be made worse by the stress of an MRI scan, such as severe claustrophobia, anxiety or panic disorders, uncontrolled high blood pressure, or seizure disorders.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Noor K Al-Tameemi, PhD student candidate, Nottingham Digestive Diseases Centre & NIHR Nottingham Biomedical Research Centre, Nottingham, University Hospitals NHS Trust and the University of Nottingham, Queens Medical Centre Nottingham, NG7 2UH

Phone: 0044 01158231149

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Nottingham
Registry
ClinicalTrials.gov
Start date
10 June 2025
Est. completion
31 March 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Quantification of blood markers contributing to systemic inflammation pathway (TNFα (pg/mL), IL-6 (pg/mL), IL-10 (pg/mL), IFNᵞ (pg/mL), C-Reactive Protein (pg/mL), Zonulin (Haptoglobulin)(pg/m), IL-1β(pg/mL)).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov